Skip main navigation

Main contents starts here

Research Alliances

In recent years, pharmaceutical discovery has come to require a combination of technologies from a number of specialized fields. While continuing to improve its own R&D capabilities, Takeda actively pursues alliances with other pharmaceutical manufacturers, biotechnology companies, universities, and other research institutions to efficiently introduce key technologies.

Research Alliances with overseas research organizations and companies

Partner Country Research subject Schedule
Oxford Centre for Diabetes, Endocrinologyand Metabolism U.K. Partnership with Oxford Diabetes Centre 2002/4-
Beth Israel Deaconess Medical Center U.S Joint collaboration on diabetes and obesity field 2002/4-
XOMA Ltd. U.S Joint research on discovery, development and production technologies  of monoclonal antibody 2006/11-
LG Life Sciences S. Korea Joint collaboration on anti-obesity drugs 2007/3-
Archemix Corp. U.S. Collaboration for Discovery and Development of AptamerTherapeutics 2007/6-2010/6
Alnylam Pharmaceuticals, Inc. U.S. Collaboration for Discovery and Development of RNAi Therapeutics 2008/5-2013/5
Seattle Genetics U.S. Research collaboration on Antibody-Drug Conjugate 2009/3-
University of Washington U.S. Joint collaboration on anti-obesity drugs 2009/3-2012/3
CellCentric U.K. Exclusive licensing of one of the CellCentric’s epigenetics projects for  the development and commercialization in oncology field. 2010/2-
Dimerix Australia Research collaboration on searching of GPCR for development of  products 2010/3-
British Columbia Cancer Agency Canada Research collaboration for discovery of novel candidate targets for  cancer treatment 2010/3-2013/3
University College London U.K. Research collaboration on development of novel cancer treatment 2010/3-2014/3
University College London U.K. Research collaboration in ophthalmologic disease 2010/3-2014/3
Metabolex, Inc. U.S. Research collaboration on evaluation and validation of protein targets  for development of biological products 2010/4-
Envoy Therapeutics Inc. U.S. Research collaboration on discovering new drug targets for  schizophrenia with Envoy’s “bacTRAP®” technology
2010/10-2013/10

(*)Roche and Arius Research Inc. announced that the two companies have signed a  definitive agreement for Roche to acquire Arius on July 23, 2008.

Research Alliances with domestic research organizations and companies

Partners Research subject Schedule
Osaka University Development of novel diagnostics of lifestyle-related diseases by novel secretory factors Apr 04- Mar 07
Kyoto University Kyoto Cell / Biodynamic Simulation Oct 03- Mar 08
Kirin Brewery (Now Kyowa Hakko Kirin) Licensing-in of the human antibody technology Jul 03 -
Keio University Target discovery for molecules differentiating neuronal stem cells to neurons Apr 03- Mar 06
RIKEN (The Institute of Physical and Chemical Research) Analysis of SNPs related to pioglitazone-induced edema Feb 03- Mar 06
RIKEN (The Institute of Physical and Chemical Research) Research for human genome relating to osteoarthritis Jul 02- Mar 05
Keio University Research for human genome relating to hypertension and diabetic organopathy Mar 02- Feb 05
Shin Nippon Biomedical Laboratories Research for toxico-genomics Jan 02- Jan 06
Biomolecular Engineering Research Institute Research for application of biomolecular functions Jun 01- Mar 06
Kagoshima University Joint research on efficacy evaluation of anti-HIV drugs Oct 97- Mar 05

Skip side navigation

Skip sub navigation

Page Top